Lastly, this study did not include an analysis of the intestinal microbiome in these patients which could have been affected by PPI use or CFTR modulator use, and future studies including such information could allow for further elucidation of the underlying mechanisms contributing to the potential for an increased incidence of GI diseases seen in children with CF. The gene discussed is CFTR; the disease is cystic fibrosis.